Related Experiment Video

Updated: May 20, 2026

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

Comprehensive treatment of Huntington disease and other choreic disorders

Carlos Singer1

  • 1Center for Parkinson's Disease and Movement Disorders, Leonard M. Miller School of Medicine, University of Miami, Miami, FL 33136, USA. CSinger@med.miami.edu

Cleveland Clinic Journal of Medicine
|July 5, 2012
PubMed

Insights

Managing choreic disorders involves diagnosing the cause, treating motor symptoms, and addressing complications like depression and cognitive decline. Effective treatments vary by etiology, including specific therapies and general symptom management.

Area of Science:

  • Neurology
  • Movement Disorders
  • Neuropharmacology

Background:

  • Choreic disorders present complex management challenges.
  • Etiologies include neurodegenerative, genetic, and drug-related conditions.
  • Diagnosis requires thorough evaluation to identify underlying causes.

Purpose of the Study:

  • To review the diagnostic and management strategies for choreic disorders.
  • To highlight specific treatments for various choreic conditions.
  • To discuss the management of associated neurologic and behavioral complications.

Main Methods:

  • Literature review of diagnostic approaches for chorea.
  • Analysis of treatment options for specific choreic disorders (e.g., Huntington disease, Sydenham chorea).
  • Examination of symptomatic treatments and management of non-motor complications.

Main Results:

  • Specific treatable causes include vitamin B12 deficiency and drug-induced dyskinesia.
  • Autoimmune choreas may respond to penicillin, corticosteroids, IVIg, or plasma exchange.
  • Heredodegenerative choreas like Huntington disease can be managed with tetrabenazine or amantadine; other agents offer nonspecific symptom control.

Conclusions:

  • Comprehensive management of choreic disorders requires addressing both motor and non-motor symptoms.
  • Tailoring treatment to the specific etiology is crucial for effective patient care.
  • Caregiver support is essential in the long-term management of these complex conditions.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...